Key attributes of IMOG‑036:
IMOG‑036 exemplifies a that leverages the fine‑tuning of innate signaling pathways to achieve therapeutic benefit while sidestepping the severe inflammatory side effects that have hampered earlier STING‑targeting agents. Its progress through early clinical stages has generated optimism for a new class of drugs that can bridge the gap between broad‑spectrum immune activation and the precise, disease‑directed immunotherapy needed for chronic infections and resistant cancers. imog-036
| Year | Milestone | |------|-----------| | | High‑throughput screen of 150 k heterocyclic libraries identifies a “hit” that modestly activates STING in a reporter assay. | | 2019 | Structure‑activity relationship (SAR) campaign yields IMOG‑036 as the lead candidate, improving EC₅₀ from 12 µM (hit) to 150 nM. | | 2020 | In‑vitro ADME (absorption, distribution, metabolism, excretion) studies reveal favorable oral bioavailability (~45 %). | | 2021 | Mouse pharmacokinetics confirm a half‑life of 3.2 h and good tissue penetration, especially in lymphoid organs. | | 2022 | Proof‑of‑concept efficacy in a murine model of chronic viral infection (LCMV clone 13) shows a 2‑log reduction in viral load with a 7‑day treatment course. | | 2023 | IND‑enabling toxicology in rats and dogs demonstrates a NOAEL (no‑observed‑adverse‑effect level) of 30 mg kg⁻¹ day⁻¹. | | 2024 | Phase I first‑in‑human trial (single ascending dose) initiates in healthy volunteers, focusing on safety, pharmacokinetics, and biomarker modulation (IFN‑β, CXCL10). | | 2025 | Phase Ib/IIa trial begins in patients with persistent HPV‑related lesions, evaluating clinical response and immunologic endpoints. | Key attributes of IMOG‑036: IMOG‑036 exemplifies a that